Search research articles
Contact Us
Filters
Showing results (201-210 of 248) with videos related to
Page
of 25
Sort By:
Journal of Medicinal Chemistry
|
June 21, 1996
Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperchlorate
G L Garrison, K D Berlin, B J Scherlag, et al.
Investigational New Drugs
|
November 27, 2002
Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy
Sherry Morgan-Meadows, James P Thomas, Daniel Mulkerin, et al.
European Journal of Drug Metabolism and Pharmacokinetics
|
April 1, 1995
Metabolism and metabolite pharmacokinetics of BRB-I-28, a class Ib antiarrhythmic agent
C L Chen, S Sangiah, D W Bourne, et al.
American Journal of Clinical Oncology
|
April 8, 2006
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer
Albert Craig Lockhart, Gillian F Cropp, Jordan D Berlin, et al.
Journal of Medicinal Chemistry
|
June 1, 1984
Synthesis, conformational analysis, and antiarrhythmic properties of 7-benzyl-3-thia-7-azabicyclo[3.3.1]nonan-9-one, 7-benzyl-3-thia-7-azabicyclo[3.3.1]nonane hydroperchlorate, and 7-benzyl-9-phenyl-3-thia-7-azabicyclo[3.3.1]nonan-9-ol hydroperchlorate and derivatives: single-crystal X-ray diffraction analysis and evidence for chair-chair and chair-boat conformers in the solid state
B R Bailey, K D Berlin, E M Holt, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 24, 2016
Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer
Emily Chan, Lori R Arlinghaus, Dana B Cardin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2015
A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors
Laura W Goff, Roger B Cohen, Jordan D Berlin, et al.
Journal of Medicinal Chemistry
|
September 10, 1999
Synthesis, structure-activity relationships, and RARgamma-ligand interactions of nitrogen heteroarotinoids
A Dhar, S Liu, J Klucik, et al.
Journal of Medicinal Chemistry
|
August 1, 1987
Heteroarotinoids. Synthesis, characterization, and biological activity in terms of an assessment of these systems to inhibit the induction of ornithine decarboxylase activity and to induce terminal differentiation of HL-60 cells
L W Spruce, S N Rajadhyaksha, K D Berlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2011
Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors
Igor Puzanov, Wooin Lee, Alice P Chen, et al.
Page
of 25
Search research articles
Search
Showing results (201-210 of 248) with videos related to
Sort By:
Page
of 25
Journal of Medicinal Chemistry
|
June 21, 1996
Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperchlorate
G L Garrison, K D Berlin, B J Scherlag, et al.
Investigational New Drugs
|
November 27, 2002
Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy
Sherry Morgan-Meadows, James P Thomas, Daniel Mulkerin, et al.
European Journal of Drug Metabolism and Pharmacokinetics
|
April 1, 1995
Metabolism and metabolite pharmacokinetics of BRB-I-28, a class Ib antiarrhythmic agent
C L Chen, S Sangiah, D W Bourne, et al.
American Journal of Clinical Oncology
|
April 8, 2006
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer
Albert Craig Lockhart, Gillian F Cropp, Jordan D Berlin, et al.
Journal of Medicinal Chemistry
|
June 1, 1984
Synthesis, conformational analysis, and antiarrhythmic properties of 7-benzyl-3-thia-7-azabicyclo[3.3.1]nonan-9-one, 7-benzyl-3-thia-7-azabicyclo[3.3.1]nonane hydroperchlorate, and 7-benzyl-9-phenyl-3-thia-7-azabicyclo[3.3.1]nonan-9-ol hydroperchlorate and derivatives: single-crystal X-ray diffraction analysis and evidence for chair-chair and chair-boat conformers in the solid state
B R Bailey, K D Berlin, E M Holt, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 24, 2016
Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer
Emily Chan, Lori R Arlinghaus, Dana B Cardin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2015
A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors
Laura W Goff, Roger B Cohen, Jordan D Berlin, et al.
Journal of Medicinal Chemistry
|
September 10, 1999
Synthesis, structure-activity relationships, and RARgamma-ligand interactions of nitrogen heteroarotinoids
A Dhar, S Liu, J Klucik, et al.
Journal of Medicinal Chemistry
|
August 1, 1987
Heteroarotinoids. Synthesis, characterization, and biological activity in terms of an assessment of these systems to inhibit the induction of ornithine decarboxylase activity and to induce terminal differentiation of HL-60 cells
L W Spruce, S N Rajadhyaksha, K D Berlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2011
Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors
Igor Puzanov, Wooin Lee, Alice P Chen, et al.
Page
of 25